In this week’s episode of the Xtalks Life Science Podcast, host Ayesha Rashid, Senior Life Science Journalist at Xtalks, spoke with Joseph Sinkule, CEO, Founder and the Chairman of the Board of Directors at Klotho Neurosciences, a biogenetics company developing cell and gene therapies using a patented, secreted form of the “anti-aging” human α-Klotho gene for the treatment of neurodegenerative, age-related disorders such as Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease and others.

Dr. Sinkule has over 40 years of drug, biologic and medical device R&D and commercialization experience. He has managed over eight drug and biotech products successfully through FDA approval to market, as well as five medical devices and eight in vitro diagnostics.

After serving in academics and then in industry, Dr. Sinkule has evolved into a successful businessman and entrepreneur. He has led teams of all sizes, managed CROs and CDMOs, serves on two company boards and regularly advises venture capital firms, investment banks and pharmaceutical and biotech companies at all stages.

Tune in to learn more about targeting pathways of aging in diseases like Alzheimer’s and ALS.

For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/

Follow Us on Social Media

Twitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

In this week’s episode of the Xtalks Life Science Podcast, host Ayesha Rashid, Senior Life Science Journalist at Xtalks, spoke with Ahmed Enayetallah, PhD, MBBCh, Chief Development Officer at Dompé Farmaceutici, a company founded as the first compounding pharmacy in Milan, Italy, which has grown into a global biopharmaceutical company over 130 years.

Currently, the company has a therapeutic pipeline focused on nerve growth factor (NGF)-based therapeutics in ocular diseases, including non-arteritic anterior ischemic optic neuropathy (NAION). Dompé has been a pioneer in translating NGF biology into medicine, building on decades of research by Nobel laureate Dr. Rita Levi-Montalcini.

Dr. Enayetallah has a robust background in clinical research and deep expertise in drug development. His career has spanned several high-profile leading roles at pharmaceutical and biotechnology companies such as Amgen, Biogen, Pfizer and Alexion. He has led efforts in personalized medicine and oversaw multiple successful clinical programs that brought novel therapies to patients with high unmet needs. Prior to joining Dompé, he led the development organization at BlueRock Therapeutics.

Dr. Enayetallah earned his medical degree from the University of Cairo and completed his PhD in Pharmacology and Toxicology at the University of Connecticut.

Tune in to learn more about NGF biology and how it is being leveraged therapeutically in ocular diseases with high unmet need.

For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/

Follow Us on Social Media

Twitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

In this week’s episode of the Xtalks Life Science Podcast, host Ayesha Rashid, Senior Life Science Journalist at Xtalks, spoke with Jason Matuszewski, chairman, CEO and co-founder of BioStem Technologies, a company developing perinatal tissue allografts for regenerative therapies.

The applications of the allografts, developed using the company’s proprietary processing method, include wound care, limb saving in conditions like diabetic foot ulcers and treating wounds and amputations of veterans.

After beginning his career as a technical engineer at SC Johnson and later leading process and quality initiatives at companies like ATI Ladish Forging, Nemak and HUSCO International, Jason’s work with the Juvenile Diabetes Research Foundation inspired his move into biotech. At BioStem, he’s overseen optimized tissue sourcing, the build-out of a 6,000-square-foot, fully FDA- and AATB-compliant tissue processing facility and the growth of a high-performing team.

Jason has a Bachelor of Science (BS) in Mechanical Engineering Technology, is a Six Sigma Black Belt and serves on the AATB Processing and Distribution Council and BioFlorida’s Government Affairs Committee.

Tune in to learn more about cutting edge developments in regenerative medicine and wound care.

For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/

Follow Us on Social Media

Twitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

In this week’s episode of the Xtalks Life Science Podcast, host Ayesha Rashid, Senior Life Science Journalist at Xtalks, spoke with Michelle Hoffmann, PhD, Executive Director of the Chicago Biomedical Consortium (CBC).

CBC is a consortium of biomedical researchers across Northwestern University, the University of Illinois at Chicago and the University of Chicago supported by the Searle Funds at The Chicago Community Trust. The CBC’s mission is to stimulate collaboration among scientists to accelerate discovery that will transform biomedical research and improve human health.

At the CBC, Dr. Hoffmann is reshaping the organization to train local PhD talent in early-stage commercialization and fund high-potential biopharma innovations from Chicago’s universities.

Previously, she served as Senior Vice President of Deep Tech at P33 and spent 15 years helping life sciences companies grow as a senior vice president at Back Bay Life Science Advisors, where she worked on major transactions including platform and asset deals with Gilead and AbbVie.

Dr. Hoffmann has a PhD in molecular and cellular biology from the University of California Berkeley and completed a postdoctoral fellowship at Brandeis University.

For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/

Follow Us on Social Media

Twitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

In this week’s episode of the Xtalks Life Science Podcast, host Ayesha Rashid, Senior Life Science Journalist at Xtalks, spoke with Stacey Adam, PhD, Vice President at the Foundation for the National Institutes of Health (FNIH), where she leads major public-private partnerships, including RECOVER-Treating Long COVID, the Biomarkers Consortium and several Accelerating Medicines Partnerships including the Partnership For Accelerating Cancer Therapies (PACT) and the Lung-MAP trial.

Dr. Adam also helps design new collaborations in areas such as pediatric medical devices, cancer systems biology and new approach methodologies.

Prior to FNIH, Dr. Adam worked in Deloitte’s Federal Life Sciences and Healthcare Strategy practice. She completed an NIH- and American Cancer Society-supported postdoctoral fellowship at Stanford and earned her PhD in Pharmacology with a Certificate in Mammalian Toxicology from Duke University.

Tune in to hear about FNIH’s initiatives fostering public-private partnerships to accelerate biomedical research and therapeutic development.

For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/

Follow Us on Social Media

Twitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

In this week’s episode of the Xtalks Life Science Podcast, host Ayesha Rashid, Senior Life Science Journalist at Xtalks, spoke with Elizabeth Jeffords, CEO, Iolyx Therapeutics, which is developing targeted therapies to address inflammation in ocular disease.

Elizabeth is a seasoned biotech leader with experience spanning company building, fundraising, clinical development, major product launches and a >$9 billion global P&L.

Before Iolyx, she served as Chief Commercial & Strategy Officer at Alkahest and held leadership roles at Genentech and Roche. An angel investor with Portfolia, she serves on several boards, including the boards of Iolyx, Ashvattha and Biotechnology Innovation Organization (BIO).

Elizabeth holds a Bachelor of Science (BS) in Biology & Management from Yale and a Masters of Business & Technology from UNSW, Australia, which she attended as a Fulbright Scholar.

Tune in to learn more about addressing inflammation in ocular diseases such as dry eye disease and more.

For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/

Follow Us on Social Media

Twitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

In this week’s episode of the Xtalks Life Science Podcast, host Ayesha Rashid, Senior Life Science Journalist at Xtalks, spoke with Ben Hwang, PhD, Chairman and CEO of Profusa, Inc., a company developing a platform of new generation bioengineered, biointegrated sensors for the real-time, continuous monitoring of body chemistry for chronic disease management and health.

The sensors detect and continuously transmit medical-grade data for personal and medical use.

Dr. Hwang has served as Profusa’s Chairman of the Board and CEO since January 2012. Prior to Profusa, Dr. Hwang served in a variety of leadership roles at Life Technologies Corp. (acquired by Thermo Fisher Scientific, Inc.), including President of the Asia Pacific Region and Head of the qPCR Division. Prior to joining Life Technology, Dr. Hwang was a consultant with McKinsey & Company.

Dr. Hwang received his MA in Biology and PhD in Biology from The Johns Hopkins University.

Tune in to learn more about how innovative, medical-based approaches in continuous health monitoring can help manage health and chronic diseases such as diabetes.

For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/

Follow Us on Social Media

Twitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

In this week’s episode of the Xtalks Life Science Podcast, host Ayesha Rashid, Senior Life Science Journalist at Xtalks, spoke with Sharon Rosenzweig-Lipson, PhD, Chief Scientific Officer (CSO) at Life Biosciences, a company advancing cellular rejuvenation gene therapies to treat age-related diseases.

The company is targeting eye diseases like glaucoma and non-arteritic anterior ischemic optic neuropathy (NAION).

Dr. Rosenzweig-Lipson has held leadership positions in both big pharma and small biotechnology companies over the course of her 30+ year career, which has included roles at American Cyanamid (now Pfizer), advancing programs from the early exploratory phase through to Phase IIB. Afterwards, she spent the next 12 years at AgeneBio where she served as Vice President of R&D.

Dr. Rosenzweig-Lipson is globally recognized for her scientific and strategic leadership, having led global translational alliances. She received her BA in the biological basis of behavior from the University of Pennsylvania and her PhD in psychology (in behavioral neuroscience) from Harvard University.

Tune in to hear about novel approaches designed to reverse cellular aging, including Life Bioscience’s work in advancing a first-of-its kind gene therapy.

For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/

Follow Us on Social Media

Twitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured